Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report

Chemotherapy. 2016;61(5):236-9. doi: 10.1159/000443762. Epub 2016 Mar 1.

Abstract

Subacute cutaneous lupus erythematosus (SCLE) is a rare eruption related to several pharmacological and chemotherapy agents. We present a 63-year-old female with recurrent epithelial ovarian cancer who developed SCLE after administration of gemcitabine. Following discontinuation of gemcitabine and after oral steroid treatment, all skin lesions disappeared. In view of the extensive use of gemcitabine in recurrent ovarian cancer, it is important to be aware of the possibility of SCLE occurrence in these patients.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Anti-Inflammatory Agents / therapeutic use
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Female
  • Gemcitabine
  • Humans
  • Lupus Erythematosus, Cutaneous / drug therapy
  • Lupus Erythematosus, Cutaneous / etiology*
  • Lymph Nodes / metabolism
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / surgery
  • Positron Emission Tomography Computed Tomography
  • Prednisone / therapeutic use
  • Skin / metabolism
  • Skin / pathology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Prednisone
  • Gemcitabine